Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Atomera Incorporated (ATOM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Atomera Incorporated — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Atomera Incorporated trades at $6.69 (market cap $256.50M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 155.5× Atomera Incorporated's market cap, and Atomera Incorporated is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | ATOM | |
|---|---|---|
Market Cap | $39.89B | $256.50M |
Sector | Health | Technology |
52-Week High | $491.22 | $12.11 |
52-Week Low | $278.09 | $1.99 |
Enterprise Value | $38.15B | $216.71M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
ATOM trades at $6.63, down 2.93% with bearish technical signals. The company shows severe financial strain with negative gross profit margin of -520.83% and net income margin of -29,219.44% for 2025. Recent earnings misses and negative cash flow highlight operational challenges, though analyst consensus remains 100% buy rating based on technology licensing potential in semiconductor materials.
Outlook remains speculative with significant execution risk. The company's GaN-on-Silicon technology partnerships with Synopsys offer potential upside, but current financial metrics and consistent losses warrant caution. Investment opportunity exists only for risk-tolerant investors betting on technology adoption breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Atomera Incorporated
Atomera is a semiconductor materials engineering company. Its Mears Silicon Technology (MST) is a patented thin film that enhances transistor performance, power efficiency, and cost for global chip manufacturers.
Read more on ATOM →
